MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 04-22-2025
Danaher Corporation Total Assets 2011-2025 | DHR
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Danaher Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.5 B | 84.5 B | 84.4 B | 83.2 B | 76.2 B | 62.1 B | 47.8 B | 46.6 B | 45.3 B | 48.2 B | 37 B | 34.7 B | 32.9 B | 29.9 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 84.5 B | 29.9 B | 56.5 B |
Quarterly Total Assets Danaher Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 79.1 B | 77.5 B | - | - | - | 81.8 B | 83.4 B | 83.2 B | 82.5 B | 78 B | 83.2 B | 76.2 B | 76.2 B | 76.2 B | 76.2 B | 62.1 B | 62.1 B | 62.1 B | 62.1 B | 47.8 B | 47.8 B | 47.8 B | 47.8 B | 46.6 B | 46.6 B | 46.6 B | 46.6 B | 45.3 B | 45.3 B | 45.3 B | 45.3 B | 48.2 B | 48.2 B | 48.2 B | 48.2 B | 37 B | 37 B | 37 B | 37 B | 34.7 B | 34.7 B | 34.7 B | 34.7 B | 32.9 B | 32.9 B | 32.9 B | 32.9 B | 29.9 B | 29.9 B | 29.9 B | 29.9 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 83.4 B | 29.9 B | 51.9 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 19.05 | 0.34 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 21.0 | 1.82 % | $ 226 M |  China |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 0.18 | -1.55 % | $ 5.28 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 39.22 | -0.24 % | $ 1.09 B | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.5 | -1.87 % | $ 298 M | Israel |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.51 | 0.67 % | $ 1.92 M | USA |
 |
Exact Sciences Corporation
EXAS
|
5.93 B | $ 101.9 | - | $ 18.9 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
6.26 B | $ 66.82 | -0.37 % | $ 25.8 B | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 26.28 | -0.79 % | $ 795 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 18.79 | -1.49 % | $ 1.01 B | USA |
 |
Celcuity
CELC
|
245 M | $ 99.21 | -0.71 % | $ 3.91 B | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
21.6 M | $ 3.11 | -0.32 % | $ 99.2 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
26.9 B | $ 226.18 | -0.65 % | $ 41 B | USA |
 |
Guardant Health
GH
|
1.49 B | $ 102.07 | 1.46 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
1.03 B | $ 6.17 | - | $ 559 M | USA |
 |
ENDRA Life Sciences
NDRA
|
4.45 M | $ 4.55 | -4.41 % | $ 2.44 M | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 7.05 | -0.07 % | $ 1.53 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
29 B | $ 27.19 | -0.75 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
270 M | $ 7.93 | -0.5 % | $ 470 M | USA |
 |
Quidel Corporation
QDEL
|
1.87 B | $ 29.0 | -1.02 % | $ 1.22 B | USA |
 |
National Research Corporation
NRC
|
122 M | $ 18.42 | -1.26 % | $ 452 M | USA |
 |
RadNet
RDNT
|
3.29 B | $ 71.33 | -0.22 % | $ 5.21 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 131.5 | -0.94 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
7.53 B | $ 201.1 | -0.44 % | $ 10.3 B | USA |
 |
Soleno Therapeutics
SLNO
|
331 M | $ 45.22 | -2.32 % | $ 1.82 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 174.8 | -0.4 % | $ 19.4 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 6.61 | -1.64 % | $ 857 M | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 252.06 | -0.4 % | $ 21.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 182.26 | -0.4 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
3.29 B | $ 681.09 | -0.18 % | $ 56.2 B | USA |
 |
Lantheus Holdings
LNTH
|
1.98 B | $ 66.97 | -0.28 % | $ 4.63 B | USA |
 |
Mettler-Toledo International
MTD
|
3.24 B | $ 1 404.2 | -0.72 % | $ 29.8 B |  Schweiz |